A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Conditions:   Minimal Residual Disease;   KRAS G12D;   KRAS G12R;   NRAS G12D;   NRAS G12R;   Pancreatic Ductal Adenocarcinoma;   Colorectal Cancer;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Cholangiocarcinoma;   Bile Duct Cancer;   Gallbladder Carcinoma
Intervention:   Drug: ELI-002 2P
Sponsor:   Elicio Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments